YOLFTbeta
Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. Common Stock

BCAX · NASDAQ · Healthcare / Biotechnology

10.02USD-0.09 (-0.89%)

Price History

Full chart

Market Stats

Previous Close10.11
Open9.96
Day Range9.71 – 10.14
52-Week Range11.81 – 30.99
Volume1.52M
Market Cap1.27B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.07
Dividend Yield0.00%
Beta-0.82
50-Day Avg24.76
200-Day Avg21.32

About

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Claire Mazumdar Clemon M.B.A., Ph.D.
  • Employees103
  • Headquarters116 Huntington Avenue, Boston, MA, United States, 02116, USA
  • Websitehttps://www.bicara.com

Leadership

  • Dr. Claire Mazumdar Clemon M.B.A., Ph.D.CEO & Director · b. 1989
  • Mr. Ryan Cohlhepp Pharm.D.President, COO & Director · b. 1977
  • Ms. Jennifer LarsonCFO, Treasurer & Principal Accounting Officer · b. 1975
  • Ms. Rachel FrankVice President of Investor Relations and Corporate Communications
  • Ms. Lara S. Meisner J.D.Chief Legal Officer, Compliance Officer & Corporate Secretary · b. 1972
  • Ms. Pauline DufresneChief People Officer
  • Ms. Rachel SalazarSVP of R&D Strategy and Operations
  • Ms. Sathish Hasige Ph.D.Senior VP and Head of Technical Operations & Supply Chain
  • Ms. Angela WindtVP & Head of Regulatory Affairs
  • Dr. Jeltje Schulten M.B.A., M.D.Senior Vice President of Clinical & Medical Affairs

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Cost of Revenue10.00K19.00K56.00K-
Gross Profit-10.00K-19.00K-56.00K-
Operating Expense37.65M39.87M82.33M-
Operating Income-37.66M-39.89M-82.39M-155.60M
EBITDA-37.72M-51.96M-67.75M-137.63M
Net Income-37.84M-51.98M-68.00M-137.95M
R&D31.31M30.62M63.62M125.10M
Interest Expense112.00K0--

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets6.70M233.98M569.20M430.99M
Total Liabilities23.98M15.47M77.32M29.54M
Total Equity-17.28M218.51M491.88M401.45M
Cash4.16M230.44M489.71M96.69M
Total Debt-657.00K738.00K1.71M
Net Debt-4.16M-229.78M-488.97M-94.97M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-32.08M-45.63M-74.75M-106.83M
Investing Cash Flow-192.00K-586.00K-9.00K-318.45M
Financing Cash Flow31.70M272.50M334.03M32.26M
Capital Expenditure192.00K586.00K71.00K280.00K
Free Cash Flow-32.27M-46.21M-74.82M-107.11M
FCF to OCF100.60%101.28%100.09%100.26%

Earnings

Report DateAug 28, 2024Nov 12, 2024Mar 27, 2025May 13, 2025Aug 12, 2025Nov 10, 2025Mar 26, 2026May 11, 2026Aug 11, 2026Nov 9, 2026
EPS Estimate-0.43-0.50-0.28-0.40-0.54-0.53-0.65-0.65-0.77-0.84
EPS Actual-0.45-1.60-0.39-0.68-0.50-0.67-0.68-0.93-0.82-
Surprise-4.65%-220.00%-38.05%-70.00%7.41%-26.42%-3.98%-43.08%-6.49%-
Timing-Pre-market-Pre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap1.27B
Enterprise Value859.79M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.89
EPS-3.07
Book Value7.11
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-201.83M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-41.01%
Return on Assets-26.14%
Shares Outstanding66.17M
Shares Float36.90M
Beta-0.82
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 34.54
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
107.61%
Insiders
10.07%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    7.26M10.97%
  • T. Rowe Price Investment Management,Inc.
    6.61M9.98%
  • Siren, L.L.C.
    5.80M8.77%
  • Vestal Point Capital LP
    5.42M8.20%
  • Deep Track Capital, LP
    4.10M6.20%
  • HHG PLC
    3.34M5.05%
  • Red Tree Management, LLC
    3.16M4.78%
  • TPG GP A, LLC
    3.01M4.55%
  • BlackRock Inc
    2.84M4.30%
  • Omega Fund Management LLC
    2.39M3.62%
  • Royalty Pharma Sub-Manager, LLC
    2.39M3.61%
  • FMR Inc
    2.10M3.17%
  • Vanguard Capital Management, LLC
    1.77M2.68%
  • Franklin Templeton Inc
    1.62M2.45%
  • State Street Corp
    1.42M2.15%
  • T. Rowe Price Associates, Inc.
    1.38M2.08%

Top Fund Holders

  • T. Rowe Price Small-Cap Stock
    1.89M2.86%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.68M2.53%
  • State Street® SPDR® S&P® Biotech ETF
    1.16M1.75%
  • iShares Russell 2000 ETF
    1.13M1.71%